Plasma microRNA-100 is associated with coronary plaque vulnerability.

BACKGROUND Although numerous studies have reported altered plasma levels of various microRNAs (miRNAs) in patients with cardiovascular disease, there are no data on the relationship between plasma miRNAs and vulnerable coronary plaque. In this study, we investigated whether plasma miRNAs might be a sensitive marker of coronary plaque vulnerability. METHODS AND RESULTS Integrated backscatter intravascular ultrasound (IB-IVUS) was performed in 32 consecutive patients with angina pectoris who underwent percutaneous coronary intervention. Three-dimensional analysis of IB-IVUS was performed to determine the percentage of lipid volume (%LV) and fibrous volume (%FV). Circulating miRNAs were measured in EDTA-plasma simultaneously obtained from the aorta and the coronary sinus (CS). Muscle-enriched (miR-133a, miR-208a, miR-499), vascular-enriched (miR-92a, miR-100, miR-126, miR-127, miR-145), and myeloid cell-enriched miRNAs (miR-155, miR-223) were measured. Plasma miR-100 was higher in the CS than in the aorta, but there were no significant differences in the levels of other miRNAs between the aorta and CS. Plasma miR-100 in the aorta was positively correlated with %LV (r=0.48, P<0.01) and negatively correlated with %FV (r=-0.41, P<0.05). Importantly, transcoronary concentration gradient of circulating miR-100 was more strongly correlated with %LV (r=0.53, P<0.01) and %FV (r=-0.56, P<0.01). CONCLUSIONS miR-100 might be released into the coronary circulation from vulnerable coronary plaques. This study provides insights into the role of miRNAs in coronary atherosclerotic disease.

[1]  Yang Zhang,et al.  Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation. , 2013, Cardiovascular research.

[2]  Manxiang Li,et al.  Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice. , 2013, International journal of molecular medicine.

[3]  Sonya S. Noor,et al.  Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood. , 2013, Atherosclerosis.

[4]  C. Fernández-Hernando,et al.  MicroRNAs and Atherosclerosis , 2013, Current Atherosclerosis Reports.

[5]  K. Kozuma,et al.  Validity and reliability of new intravascular ultrasound analysis software for morphological measurement of coronary artery disease. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[6]  F. Cipollone,et al.  MicroRNAs and atherosclerosis: new actors for an old movie. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  J. Chiu,et al.  Roles of microRNAs in atherosclerosis and restenosis , 2012, Journal of Biomedical Science.

[8]  Tevfik F Ismail,et al.  A histological and clinical comparison of new and conventional integrated backscatter intravascular ultrasound (IB-IVUS). , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[9]  A. Zernecke,et al.  MicroRNAs in the regulation of immune cell functions – implications for atherosclerotic vascular disease , 2012, Thrombosis and Haemostasis.

[10]  A. Tijsen,et al.  Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? , 2012, Circulation research.

[11]  M. Zile,et al.  Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction , 2011, Circulation. Cardiovascular genetics.

[12]  S. Fichtlscherer,et al.  Transcoronary Concentration Gradients of Circulating MicroRNAs , 2011, Circulation.

[13]  A. Marchetti,et al.  A Unique MicroRNA Signature Associated With Plaque Instability in Humans , 2011, Stroke.

[14]  M. Akaike,et al.  Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. , 2011, Journal of cardiology.

[15]  J. Sluijter,et al.  MicroRNA-100 Regulates Neovascularization by Suppression of Mammalian Target of Rapamycin in Endothelial and Vascular Smooth Muscle Cells , 2011, Circulation.

[16]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[17]  Stefanie Dimmeler,et al.  Circulating MicroRNAs in Patients With Coronary Artery Disease , 2010, Circulation research.

[18]  Federica Limana,et al.  Circulating microRNAs are new and sensitive biomarkers of myocardial infarction , 2010, European heart journal.

[19]  Yue Li,et al.  Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. , 2010, European heart journal.

[20]  M. Hristov,et al.  Delivery of MicroRNA-126 by Apoptotic Bodies Induces CXCL12-Dependent Vascular Protection , 2009, Science Signaling.

[21]  J. Waldron,et al.  Significance of Plk1 regulation by miR‐100 in human nasopharyngeal cancer , 2009, International journal of cancer.

[22]  M. Lindsay,et al.  microRNAs and the immune response , 2009, Current opinion in pharmacology.

[23]  Jianzhong Xi,et al.  Real-time polymerase chain reaction microRNA detection based on enzymatic stem-loop probes ligation. , 2009, Analytical chemistry.

[24]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[25]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[26]  Joshua T. Mendell,et al.  MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1 , 2008, Proceedings of the National Academy of Sciences.

[27]  E. Olson,et al.  MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. , 2007, The Journal of clinical investigation.

[28]  H. Izawa,et al.  Impact of metabolic syndrome on tissue characteristics of angiographically mild to moderate coronary lesions integrated backscatter intravascular ultrasound study. , 2007, Journal of the American College of Cardiology.

[29]  T. Kodama,et al.  Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[30]  H. Fujita,et al.  Assessment of vulnerable plaques causing acute coronary syndrome using integrated backscatter intravascular ultrasound. , 2006, Journal of the American College of Cardiology.

[31]  Peter Libby,et al.  Vascular biology of atherosclerosis: overview and state of the art. , 2003, The American journal of cardiology.

[32]  M. Arai,et al.  In Vivo Quantitative Tissue Characterization of Human Coronary Arterial Plaques by Use of Integrated Backscatter Intravascular Ultrasound and Comparison With Angioscopic Findings , 2002, Circulation.

[33]  T. Wakatsuki,et al.  Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[34]  T. Murohara,et al.  Lipid-rich plaques predict non-target-lesion ischemic events in patients undergoing percutaneous coronary intervention. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[35]  P. Bodary,et al.  Vascular biology of atherosclerosis , 2006 .